Grant opportunity · PAR-25-297
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Who can apply (as listed)
- Independent school districts
- Special district governments
- Private institutions of higher education
- Public and state-controlled institutions of higher education
- For-profit organizations (other than small businesses)
- County governments
- Native American tribal organizations (other than federally recognized governments)
- Small businesses
- Others (see the opportunity text)
- Nonprofits without 501(c)(3) status (other than institutions of higher education)
- State governments
- City or township governments
- Public housing authorities / Indian housing authorities
- Native American tribal governments (federally recognized)
- Nonprofits with 501(c)(3) status (other than institutions of higher education)
The goal of this Notice of Funding Opportunity (NOFO) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms. Participants in this program will receive funding for therapy development activities such as medicinal chemistry; pharmacokinetics (PK); Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET); efficacy in animal models; development of biomarkers for target engagement; formulation development; chemical synthesis under Good Manufacturing Practices (GMP); Investigational New Drug (IND) enabling studies; and initial Phase I clinical testing. Applications not responsive to this NOFO include research on basic mechanisms of disease or mechanisms of drug action; development ofrisk, diagnostic, prognostic, predictive, and preventionbiomarkers, devices, non-pharmacological …
Excerpt as published. The full synopsis, required forms, and any amendments are on the official listing.
GrantSet indexes public records and is not the official application channel. Responses and applications go through Grants.gov only — the official notice there controls if anything shown here differs.